Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Fascioscapulohumeral Muscular Dystrophy: full-pipeline trial registry
2 of 3 indexed Fascioscapulohumeral Muscular Dystrophy trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Fascioscapulohumeral Muscular Dystrophy: 3 US clinical trials tracked, 2 recruiting.
Fascioscapulohumeral Muscular Dystrophy is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Avidity Biosciences, running 2 of these trials.
Enrollment posture brief
Registry condition fascioscapulohumeral-muscular-dystrophy
OPEN 2 | RECR 67% | LATE 1 | EARLY 1 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Fascioscapulohumeral Muscular Dystrophy lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Fascioscapulohumeral Muscular Dystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Fascioscapulohumeral Muscular Dystrophy is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Avidity Biosciences
NCT07038200
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
University of Missouri-Columbia
NCT07478172
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Avidity Biosciences
NCT05747924
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Fascioscapulohumeral Muscular Dystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Fascioscapulohumeral Muscular Dystrophy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Fascioscapulohumeral Muscular Dystrophy page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Fascioscapulohumeral Muscular Dystrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Avidity Biosciences sponsors the most Fascioscapulohumeral Muscular Dystrophy trials on record, review their full trial history before evaluating a specific study. See Avidity Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fascioscapulohumeral Muscular Dystrophy condition card totals 3 registered trials; most-linked intervention Placebo; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.